JP2011510303A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011510303A5 JP2011510303A5 JP2010543281A JP2010543281A JP2011510303A5 JP 2011510303 A5 JP2011510303 A5 JP 2011510303A5 JP 2010543281 A JP2010543281 A JP 2010543281A JP 2010543281 A JP2010543281 A JP 2010543281A JP 2011510303 A5 JP2011510303 A5 JP 2011510303A5
- Authority
- JP
- Japan
- Prior art keywords
- biomolecule
- borate
- apatite chromatography
- ionic species
- chromatography support
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 65
- 229910052586 apatite Inorganic materials 0.000 claims description 29
- 238000004587 chromatography analysis Methods 0.000 claims description 29
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 claims description 29
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 28
- 241000894007 species Species 0.000 claims description 22
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 14
- 239000011575 calcium Substances 0.000 claims description 14
- 229910052791 calcium Inorganic materials 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- 150000002500 ions Chemical class 0.000 claims description 11
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 10
- 238000010828 elution Methods 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 8
- 230000003139 buffering effect Effects 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- 229910021538 borax Inorganic materials 0.000 claims description 4
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 4
- WUUHFRRPHJEEKV-UHFFFAOYSA-N tripotassium borate Chemical compound [K+].[K+].[K+].[O-]B([O-])[O-] WUUHFRRPHJEEKV-UHFFFAOYSA-N 0.000 claims description 4
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims description 4
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical group C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 229910052587 fluorapatite Inorganic materials 0.000 claims description 2
- 229940050410 gluconate Drugs 0.000 claims description 2
- 229940097042 glucuronate Drugs 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 2
- 229940001447 lactate Drugs 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 229920000620 organic polymer Polymers 0.000 claims description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical group [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- PHZLMBHDXVLRIX-UHFFFAOYSA-M potassium lactate Chemical compound [K+].CC(O)C([O-])=O PHZLMBHDXVLRIX-UHFFFAOYSA-M 0.000 claims description 2
- 239000001521 potassium lactate Substances 0.000 claims description 2
- 235000011085 potassium lactate Nutrition 0.000 claims description 2
- 229960001304 potassium lactate Drugs 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 229940076788 pyruvate Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000001540 sodium lactate Substances 0.000 claims description 2
- 229940005581 sodium lactate Drugs 0.000 claims description 2
- 235000011088 sodium lactate Nutrition 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1151308P | 2008-01-18 | 2008-01-18 | |
| US61/011,513 | 2008-01-18 | ||
| US6266308P | 2008-01-28 | 2008-01-28 | |
| US61/062,663 | 2008-01-28 | ||
| US6985908P | 2008-03-19 | 2008-03-19 | |
| US61/069,859 | 2008-03-19 | ||
| US7084108P | 2008-03-27 | 2008-03-27 | |
| US61/070,841 | 2008-03-27 | ||
| US13578708P | 2008-07-24 | 2008-07-24 | |
| US61/135,787 | 2008-07-24 | ||
| US18946708P | 2008-08-20 | 2008-08-20 | |
| US61/189,467 | 2008-08-20 | ||
| PCT/US2009/031293 WO2009092010A1 (en) | 2008-01-18 | 2009-01-16 | Enhanced purification of phosphorylated and non-phosphorylated biomolecules by apatite chromatography |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011510303A JP2011510303A (ja) | 2011-03-31 |
| JP2011510303A5 true JP2011510303A5 (https=) | 2012-03-01 |
| JP5624476B2 JP5624476B2 (ja) | 2014-11-12 |
Family
ID=40876787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010543281A Active JP5624476B2 (ja) | 2008-01-18 | 2009-01-16 | アパタイトクロマトグラフィーによるリン酸化生体分子および非リン酸化生体分子の向上した精製法 |
Country Status (4)
| Country | Link |
|---|---|
| US (5) | US20090186396A1 (https=) |
| EP (4) | EP2275431A3 (https=) |
| JP (1) | JP5624476B2 (https=) |
| WO (2) | WO2009092010A1 (https=) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI456062B (zh) | 2006-09-13 | 2014-10-11 | Abbvie Inc | 細胞培養改良 |
| US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
| EP2275431A3 (en) * | 2008-01-18 | 2011-05-25 | Bio-Rad Laboratories, Inc. | Enhanced fractionation of phosphorylated and nonphosphorylated biomolecules by apatite chromotography |
| AU2009347206C1 (en) | 2008-10-20 | 2016-12-08 | Abbvie Inc. | Isolation and purification of antibodies using Protein A affinity chromatography |
| MX2011004201A (es) | 2008-10-20 | 2011-05-24 | Abbott Lab | Desactivacion viral durante purificacion de anticuerpos. |
| EP2350130B1 (en) * | 2008-10-31 | 2018-10-03 | Wyeth LLC | Purification of acidic proteins using ceramic hydroxyapatite chromatography |
| US8907059B2 (en) * | 2008-11-14 | 2014-12-09 | Bio-Rad Laboratories, Inc. | Phosphopeptide enrichment of compositions by fractionation on ceramic hydroxyapatite |
| US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| JP2011097918A (ja) * | 2009-10-07 | 2011-05-19 | Hoya Corp | 精製方法およびワクチンの製造方法 |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| MX2012008085A (es) | 2010-01-13 | 2012-09-12 | Oncomed Pharm Inc | Agentes de union notch1 y metodos de uso de los mismos. |
| WO2011088225A1 (en) | 2010-01-15 | 2011-07-21 | Bio-Rad Laboratories, Inc. | Surface neutralization of apatite |
| CN103037900B (zh) | 2010-02-24 | 2016-04-06 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
| SG183542A1 (en) | 2010-03-12 | 2012-10-30 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
| WO2011146179A2 (en) * | 2010-05-18 | 2011-11-24 | Abbott Laboratories | Apparatus and process of purification of proteins |
| WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
| US8895707B2 (en) | 2010-08-18 | 2014-11-25 | Bio-Rad Laboratories, Inc. | Elution of proteins from hydroxyapatite resins without resin deterioration |
| JP5903101B2 (ja) * | 2010-09-20 | 2016-04-13 | バイオ−ラッド ラボラトリーズ インコーポレーティッド | クロマトグラフィーにおける生成物と複合体形成した夾雑物の分離方法 |
| CA2821711C (en) * | 2010-12-15 | 2017-10-10 | Baxter International Inc. | Eluate collection using conductivity gradient |
| WO2012101671A1 (en) * | 2011-01-25 | 2012-08-02 | Jcr Pharmaceuticals Co., Ltd. | Method for production of human recombinant iduronate 2-sulfatase |
| JP5881744B2 (ja) * | 2011-02-02 | 2016-03-09 | バイオ−ラッド ラボラトリーズ インコーポレーティッド | アルカリ溶液でのアパタイトの表面中和方法 |
| EP3318571B1 (en) | 2011-03-16 | 2021-02-17 | F. Hoffmann-La Roche AG | Ion exchange chromatography with improved selectivity for the separation of polypeptide monomers, aggregates and fragments by modulation of the mobile phase |
| US8906692B2 (en) | 2011-03-29 | 2014-12-09 | Jcr Pharmaceuticals Co., Ltd. | Instrument and method for analysis of mannose 6-phosphate |
| US8911992B2 (en) * | 2011-04-28 | 2014-12-16 | Bio-Rad Laboratories, Inc. | DNA removal in target molecule purification |
| BR112014000765A2 (pt) | 2011-07-15 | 2017-06-13 | Oncomed Pharm Inc | agentes de ligação a rspo e seus usos |
| CN103814048A (zh) * | 2011-09-20 | 2014-05-21 | 生物辐射实验室股份有限公司 | 从生物分子制剂中去除杀病毒剂 |
| LT3485903T (lt) | 2011-09-23 | 2023-02-27 | Mereo Biopharma 5, Inc. | Vegf/ dll4 surišantys agentai ir jų panaudojimas |
| EP2768857B1 (en) * | 2011-10-19 | 2020-01-01 | NovImmune SA | Methods of purifying antibodies |
| JP6180425B2 (ja) | 2011-11-23 | 2017-08-23 | メディミューン，エルエルシー | Ｈｅｒ３に特異的な結合分子及びそれらの使用 |
| US9815695B2 (en) | 2012-05-30 | 2017-11-14 | Bio-Rad Laboratories, Inc. | In situ restoration of apatite-based chromatography resins |
| MX2014014951A (es) | 2012-06-06 | 2015-03-13 | Oncomed Pharm Inc | Agentes aglutinantes que modulan la trayectoria hippo y sus usos. |
| HUE049693T2 (hu) | 2012-08-31 | 2020-10-28 | Immunogen Inc | Diagnosztikai ASSAY-k és készletek a folát receptor 1 kimutatására |
| US20140073766A1 (en) * | 2012-09-07 | 2014-03-13 | Avianax Llc | METHODS FOR PURIFYING IgY ANTIBODIES |
| US20150275195A1 (en) * | 2012-10-24 | 2015-10-01 | Genzyme Corporation | Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers |
| HK1210964A1 (en) | 2012-12-04 | 2016-05-13 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| KR102343212B1 (ko) | 2013-03-27 | 2021-12-23 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전 |
| WO2015005960A1 (en) | 2013-07-12 | 2015-01-15 | Emd Millipore Corporation | Removal of fragments from a sample containing a target protein using activated carbon |
| WO2015010108A1 (en) | 2013-07-19 | 2015-01-22 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
| CA2919174A1 (en) | 2013-08-19 | 2015-02-26 | F. Hoffmann-La Roche Ag | Separation of bispecific antibodies and bispecific antibody production side products using hydroxyapatite chromatography |
| AU2014312086B2 (en) | 2013-08-30 | 2020-03-12 | Immunogen, Inc. | Antibodies and assays for detection of folate receptor 1 |
| IL298044B2 (en) | 2013-10-08 | 2024-11-01 | Immunogen Inc | Dosing regimens of anti-FOLR1 immunoconjugate |
| TW201610168A (zh) | 2013-12-02 | 2016-03-16 | 安可美德藥物股份有限公司 | 與Ｗｎｔ途徑抑制劑有關之預測性生物標記之鑑別 |
| RU2678810C2 (ru) | 2014-02-02 | 2019-02-01 | Медиммун Лимитед | ХИМЕРНЫЙ БЕЛОК, СОСТАВЛЕННЫЙ ИЗ ДОМЕНА АНТАГОНИСТА NGF И ДОМЕНА АНТАГОНИСТА TNFα |
| HUE051676T2 (hu) | 2014-04-08 | 2021-03-29 | Boston Pharmaceuticals Inc | Il-21-re specifikus kötõ molekulák és alkalmazásaik |
| MX2016012830A (es) | 2014-04-11 | 2017-01-05 | Medimmune Llc | Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos. |
| JP2016003192A (ja) * | 2014-06-16 | 2016-01-12 | ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 | 緩衝液および精製方法 |
| US10099157B2 (en) | 2014-06-23 | 2018-10-16 | Bio-Rad Laboratories, Inc. | Apatite in-situ restoration |
| CN105392569B (zh) | 2014-06-23 | 2019-08-20 | 生物辐射实验室股份有限公司 | 磷灰石预处理 |
| TW201619200A (zh) | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| DK3218406T4 (da) | 2014-11-10 | 2024-12-09 | Medimmune Ltd | Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf |
| EP3218407A1 (en) | 2014-11-11 | 2017-09-20 | Medimmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof |
| SG10202108116SA (en) | 2015-06-08 | 2021-08-30 | Debiopharm International S A | Anti-cd37 immunoconjugate and anti-cd20 antibody combinations |
| ES2887273T3 (es) | 2015-06-29 | 2021-12-22 | Immunogen Inc | Anticuerpos anti-CD123 y conjugados y derivados de los mismos |
| AU2016323968B2 (en) | 2015-09-17 | 2023-07-06 | Immunogen, Inc. | Therapeutic combinations comprising anti-FOLR1 immunoconjugates |
| EP3353204B1 (en) | 2015-09-23 | 2023-10-18 | Mereo BioPharma 5, Inc. | Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer |
| LT3370515T (lt) | 2015-10-21 | 2022-05-10 | Redcoat Solutions, Inc. | Patalinių blakių aptikimo įrenginys |
| ES2953484T3 (es) | 2015-10-21 | 2023-11-13 | Redcoat Solutions Inc | Anticuerpos monoclonales antichinches y métodos de elaboración y usos de los mismos |
| SMT202000285T1 (it) | 2015-11-10 | 2020-07-08 | Medimmune Llc | Molecole di legame specifiche per asct2 e loro usi |
| US11661438B2 (en) * | 2015-12-21 | 2023-05-30 | Pfizer, Inc. | Purification of antibody drug conjugates using a sodium phosphate gradient |
| JP6987072B2 (ja) | 2016-03-10 | 2021-12-22 | アクセレロン ファーマ インコーポレーテッド | アクチビン２型受容体結合タンパク質及びその使用 |
| US11186872B2 (en) | 2016-03-17 | 2021-11-30 | Cedars-Sinai Medical Center | Methods of diagnosing inflammatory bowel disease through RNASET2 |
| CN116217731B (zh) | 2016-04-22 | 2025-12-30 | 艾科赛扬制药股份有限公司 | Alk7结合蛋白及其用途 |
| MY194619A (en) | 2016-06-02 | 2022-12-07 | Abbvie Inc | Glucocorticoid receptor agonist and immunoconjugates thereof |
| CN110087677B (zh) | 2016-10-11 | 2023-12-08 | 生物综合治疗有限公司 | 靶向埃博拉病毒糖蛋白内部融合环的广泛中和抗体 |
| MY191324A (en) | 2016-10-26 | 2022-06-15 | Cedars Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
| US20230192896A1 (en) | 2016-11-23 | 2023-06-22 | Bioverativ Therapeutics Inc. | Bispecific antibodies binding to coagulation factor ix and coagulation factor x |
| US20210130396A1 (en) * | 2017-08-30 | 2021-05-06 | Ares Trading S.A. | Method for purifying proteins |
| WO2019043096A1 (en) * | 2017-08-30 | 2019-03-07 | Fresenius Kabi Deutschland Gmbh | METHOD FOR PURIFYING IL-6 ANTI-RECEPTOR ANTIBODIES |
| JP7332627B2 (ja) | 2018-04-25 | 2023-08-23 | プロメテウス バイオサイエンシーズ，インク． | 最適化された抗ｔｌ１ａ抗体 |
| WO2019224660A1 (ja) * | 2018-05-24 | 2019-11-28 | ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 | 吸着剤の生産方法 |
| WO2020102644A2 (en) | 2018-11-15 | 2020-05-22 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with vegf/dll4 binding agent |
| CN113227135B (zh) | 2018-12-28 | 2025-03-21 | 斯帕克斯治疗公司 | 用于治疗癌症和其他疾病的对紧密连接蛋白18.2具有特异性的结合分子、其组合物和方法 |
| CN119874910A (zh) * | 2019-06-07 | 2025-04-25 | 达因疗法公司 | 制备蛋白质-寡核苷酸复合物的方法 |
| KR20220103721A (ko) | 2019-10-24 | 2022-07-22 | 프로메테우스 바이오사이언시즈, 인크. | Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도 |
| BR112023004840A2 (pt) | 2020-09-28 | 2023-04-18 | Medimmune Ltd | Compostos e métodos para tratamento de dor |
| US11807685B2 (en) | 2021-08-05 | 2023-11-07 | The Uab Research Foundation | Anti-CD47 antibody and uses thereof |
| JP2024542939A (ja) | 2021-10-15 | 2024-11-19 | リジェネクスバイオ インコーポレイテッド | 抗体及びその使用方法 |
| WO2024169990A1 (zh) | 2023-02-13 | 2024-08-22 | 浙江大学绍兴研究院 | 双特异性抗体及其应用 |
| CN116606370B (zh) * | 2023-07-21 | 2023-09-19 | 南京松天盛科生物科技有限公司 | 一种天然IgM纯化的方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5441635A (en) * | 1986-07-05 | 1995-08-15 | Asahi Kogaku Kogyo Kabushiki Kaisha | Packing material for liquid chromatography |
| US4798886A (en) * | 1986-03-24 | 1989-01-17 | Takeda Chemical Industries, Ltd. | Mutual separation of proteins |
| JP2507339B2 (ja) * | 1986-08-11 | 1996-06-12 | 三井東圧化学株式会社 | 粗ｔＰＡの精製方法 |
| US5108919A (en) * | 1988-06-24 | 1992-04-28 | Genentech, Inc. | Dna sequences encoding yeast ubiquitin hydrolase |
| JPH084490B2 (ja) * | 1988-07-30 | 1996-01-24 | 積水化学工業株式会社 | 生物学的試料の処理装置 |
| JP3442788B2 (ja) * | 1996-02-06 | 2003-09-02 | ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 精製核酸の製法及びその使用 |
| US5843731A (en) | 1996-09-05 | 1998-12-01 | Asahi Kogaku Kogyo Kabushiki Kaisha | Method for purifying plasmid DNA on calcium phosphate compound |
| JPH10127285A (ja) * | 1996-09-05 | 1998-05-19 | Asahi Optical Co Ltd | プラスミドｄｎａの単離方法 |
| JP4160652B2 (ja) * | 1998-05-22 | 2008-10-01 | キリンファーマ株式会社 | エンド−β−Ｎ−アセチルグルコサミニダーゼ遺伝子 |
| WO2003059935A2 (en) * | 2001-12-21 | 2003-07-24 | Immunex Corporation | Methods for purifying protein |
| DE102004027816A1 (de) * | 2004-06-08 | 2006-01-05 | Bioceuticals Arzneimittel Ag | Verfahren zur Reinigung von Erythropoietin |
| EP1778255A2 (en) * | 2004-08-04 | 2007-05-02 | Allos Therapeutics, Inc. | Methods and compositions to reduce tissue irritation in parenteral formulations |
| DE102004044419B4 (de) * | 2004-09-14 | 2010-04-15 | Biotest Ag | Verfahren zur Aufreinigung eines von Willebrand Faktors mittels Hydroxylapatit-Durchlaufchromatographie |
| AU2006223180B2 (en) | 2005-03-11 | 2011-11-24 | Wyeth Llc | A method of weak partitioning chromatography |
| EP1866427A4 (en) * | 2005-03-30 | 2010-09-01 | Novo Nordisk As | METHOD OF MANUFACTURING PEPTIDES PRODUCED IN INSECT CELL LINES |
| US20100234577A1 (en) * | 2006-06-14 | 2010-09-16 | Smithkline Beecham Corporation | Methods for purifying antibodies using ceramic hydroxyapatite |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| US7999085B2 (en) | 2007-01-09 | 2011-08-16 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of protein by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| EP2275431A3 (en) * | 2008-01-18 | 2011-05-25 | Bio-Rad Laboratories, Inc. | Enhanced fractionation of phosphorylated and nonphosphorylated biomolecules by apatite chromotography |
-
2009
- 2009-01-16 EP EP20100178843 patent/EP2275431A3/en not_active Withdrawn
- 2009-01-16 WO PCT/US2009/031293 patent/WO2009092010A1/en not_active Ceased
- 2009-01-16 EP EP09701572.1A patent/EP2242762B1/en not_active Not-in-force
- 2009-01-16 EP EP09702238.8A patent/EP2238154B1/en not_active Not-in-force
- 2009-01-16 WO PCT/US2009/031298 patent/WO2009092014A1/en not_active Ceased
- 2009-01-16 JP JP2010543281A patent/JP5624476B2/ja active Active
- 2009-01-16 EP EP10178856.0A patent/EP2287174B8/en not_active Not-in-force
- 2009-01-16 US US12/355,686 patent/US20090186396A1/en not_active Abandoned
- 2009-01-16 US US12/355,665 patent/US8093364B2/en not_active Expired - Fee Related
-
2011
- 2011-12-02 US US13/310,576 patent/US9127042B2/en active Active
-
2015
- 2015-08-05 US US14/819,334 patent/US9938317B2/en not_active Expired - Fee Related
-
2018
- 2018-03-02 US US15/910,702 patent/US10919930B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011510303A5 (https=) | ||
| JP2013500711A5 (https=) | ||
| JP5624476B2 (ja) | アパタイトクロマトグラフィーによるリン酸化生体分子および非リン酸化生体分子の向上した精製法 | |
| JP5772816B2 (ja) | アフィニティークロマトグラフィー用充填剤およびイムノグロブリンを単離する方法 | |
| JP2013517284A5 (https=) | ||
| RU2015141849A (ru) | Способ очистки фактора свертывания крови viii | |
| EA201500952A1 (ru) | Способы очистки рекомбинантного adamts13 и других белков и их композиции | |
| RU2011137030A (ru) | Способы очистки малых модулярных иммунофармацевтических белков | |
| AR074015A1 (es) | Purificacion de proteinas acidas utilizando cromatografia de hidroxiapatita ceramica | |
| JP5773454B2 (ja) | アパタイトの表面中和方法 | |
| JP2007532477A5 (https=) | ||
| RU2010105312A (ru) | Хроматографические способы | |
| RU2695428C2 (ru) | СПОСОБ ПРОИЗВОДСТВА ФАКТОРА VIII, ИМЕЮЩЕГО УЛУЧШЕННОЕ СООТНОШЕНИЕ FVIII:C/FVIII:Ag | |
| JP2014507368A5 (https=) | ||
| CN102234332B (zh) | 一种重组人血白蛋白及其融合蛋白的分离纯化工艺 | |
| JP2012510500A5 (https=) | ||
| RU2011125656A (ru) | Очистка полипептидов | |
| WO2014034457A1 (ja) | ミックスモード抗体アフィニティー分離マトリックスとそれを用いた精製方法および標的分子 | |
| TW408129B (en) | Method for purifying human urinary thrombomodulin by using hydroxyapatite column | |
| JP2014518508A5 (https=) | ||
| RU2012133474A (ru) | Очистка факторов свертывания крови | |
| JP2013517259A5 (https=) | ||
| JP2014094936A (ja) | 抗体の精製方法 | |
| JP2009039038A (ja) | 被分離物質の分離方法及び精製方法 | |
| JP3476242B2 (ja) | インフルエンザｈａ蛋白の精製方法 |